Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show
Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows
Adding Darzalex (daratumumab) to the standard pre-transplant therapy…
STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment
STRO-001, Sutro Biopharma’s investigational therapy for multiple…
Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted…
Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals
Among those with blood cancers — including myeloma, lymphoma,…
FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia
The U.S. Food and Drug Administration (FDA) has approved…
